Abstract:The myeloid-derived suppressor cell (MDSC)-mediated immunosuppressive tumor microenvironment (TME), where tumor hypoxia counts for much, has greatly compromised the outcome of cancer immunotherapy. Here, we demonstrated a strategy for selectively clearing intratumoral MDSCs. Specifically, 2-[2-[2-chloro-3-[(1,3-dihydro-3,3-dimethyl-1-propyl-2H-indol-2-ylidene)ethylidene]-1-cyclohexen-1-yl]ethenyl]-3,3-dimethyl-1-propylindolium iodide (IR-780) and metformin (Met) were coloaded into mesoporous silica nanoparticles (MSNs) with CeO2 as the gatekeepers. Controlled release of cargos was achieved upon etching CeO2 with endogenous H2O2. Apart from the drug release, oxygen (O2) was also generated in this process. Importantly, the engagement of Met significantly inhibited mitochondrial respiration, thus working like an O2 economizer. Consequently, the populations and functions of tumor-infiltrated MDSCs were both dramatically reduced through selective alleviation of hypoxia at tumor sites, thus contributing to boosted immune responses. Additionally, the accumulated O2 enhanced IR780-mediated photodynamic therapy, which synergistically strengthened the antitumor efficacy of the platform. To the best of our knowledge, this is the first time to employ an O2-generated and -economized nanoplatform for selectively anergizing MDSC-mediated immunosuppression. We expect that this strategy will shed new light on the clinical cancer immunotherapy treatment.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c18180?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c18180</a>.In vitro release profile of IR780 and Met from CeO2@/Met nanoparticles in plasma. Degradation of H2O2 by CeO2 NPs and the release of O2. Positive area of Ki-67 in tumor tissues after indicated treatments. Positive area of TUNEL in tumor tissues after indicated treatments. Survival curves of B16F10 tumor-bearing mice that received indicated treatments as displayed. Plasma concentration–time curves of CeO2@/Met in mice after intravenous injection. In vivo tissue distribution in B16F10 tumor-bearing mice intravenously injected with indicated treatments at different time points. Quantification of the metastatic nodules on the lung surface of mice under different treatments. Q-PCR analyzed the mRNA level of HIF-α in tumor tissues from B16F10 tumor-bearing mice subjected to indicated treatments. Relative intensity of HIF-1α protein expression by western blotting. Standardized uptake values (SUVs) in solid tumor regions obtained from in vivo PET images taken at 1 h after the injection of 18F-MISO. Relative quantification of MDSCs (CD11b+Gr-1+) in tumor tissues following different treatments. Relative quantification of CTLs (CD3+CD8+) in tumor tissues following different treatments. ELISA assay for IL-10 and TGF-β. Relative intensity of PD-L1 protein expression by western blotting. Histology of the mouse organs collected 21 days after the intravenous injection of CeO2@/Met (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c18180/suppl_file/am0c18180_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

A macrophage membrane-coated mesoporous silica nanoplatform inhibiting adenosine A2AR via in situ oxygen supply for immunotherapy

A macrophage membrane-coated mesoporous silica nanoplatform inhibiting adenosine A2AR<i> via</i><i> in</i><i> situ</i> oxygen supply for immunotherapy

Nanoparticle-enabled concurrent modulation of phagocytosis and repolarization of macrophages for enhanced cancer immunotherapy

Boosting Cancer Immunotherapy Via the Convenient A2AR Inhibition Using a Tunable Nanocatalyst with Light-Enhanced Activity

Antibody-Decorated Nanoplatform to Reprogram Macrophage and Block Immune Checkpoint LSECtin for Effective Cancer Immunotherapy

A Multifunctional Biomimetic Nanoplatform for Relieving Hypoxia to Enhance Chemotherapy and Inhibit the PD-1/PD-L1 Axis.

Nanoreactors with Cascade Catalytic Activity Reprogram the Tumor Microenvironment for Enhanced Immunotherapy by Synchronously Regulating Treg and Macrophage Cells

Reprogramming Tumor-Immune Cell Communication with a Radiosensitive Nanoregulator for Immunotherapy

An intelligent responsive macrophage cell membrane-camouflaged mesoporous silicon nanorod drug delivery system for precise targeted therapy of tumors

A siRNA-Assisted Assembly Strategy to Simultaneously Suppress “Self” and Upregulate “Eat-Me” Signals for Nanoenabled Chemo-Immunotherapy

Suppressing the Hypoxia‐Adenosinergic Axis by a Tailored Nanoreactor for Enhanced Photothermal Immunotherapy

An "All-In-One" Immunomodulator-Engineered Clinical Translatable Immunotherapy of Advanced Hepatocellular Carcinoma

Nanoparticles (NPs)-mediated Siglec15 silencing and macrophage repolarization for enhanced cancer immunotherapy

Repolarizing Tumor-Associated Macrophages and inducing immunogenic cell Death: A targeted liposomal strategy to boost cancer immunotherapy

A Versatile Nanoplatform for Broad-Spectrum Immunotherapy by Reversing the Tumor Microenvironment

Enhanced Immunotherapy Based on Combining the Pro-phagocytosis and Anti-phagocytosis Checkpoint Blockade for Tumor Eradication

Circumventing Myeloid-Derived Suppressor Cell-Mediated Immunosuppression Using an Oxygen-Generated and -Economized Nanoplatform

Nanoscale Metal-Organic Framework Co-delivers TLR-7 Agonists and Anti-CD47 Antibodies to Modulate Macrophages and Orchestrate Cancer Immunotherapy.

Nanomedicine-based co-delivery of a calcium channel inhibitor and a small molecule targeting CD47 for lung cancer immunotherapy

Selective Manipulation of the Mitochondria Oxidative Stress in Different Cells Using Intelligent Mesoporous Silica Nanoparticles to Activate On‐Demand Immunotherapy for Cancer Treatment

A Self-amplifying ROS-sensitive Prodrug-Based Nanodecoy for Circumventing Immune Resistance in Chemotherapy-Sensitized Immunotherapy.